Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHEAD-MERIT: BNT113 + Pembrolizumab vs Pembrolizumab in HPV16+ PD-L1+ HNSCC
NCT04534205Phase 3Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Jan 2021
- Primary completion
- Apr 2029
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 21
01
Overview
A Phase 3 trial of BNT113 in head and neck squamous cell carcinoma (HNSCC), sponsored by BioNTech SE. Started Jan 2021; status: active, not recruiting.
02
Drugs
BNT113
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04534205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534205.